4D Molecular Therapeutics is a clinical-stage biotechnology company developing genetic medicines for retinal and pulmonary diseases. The company utilizes its proprietary Therapeutic Vector Evolution (TVE) platform to create customized adeno-associated virus (AAV) vectors, including the R100 vector, designed for efficient delivery to specific tissues. Its lead product candidate, 4D-150, is a genetic therapy for wet age-related macular degeneration and diabetic macular edema that delivers anti-VEGF biologics and RNA interference to inhibit vascular endothelial growth factors. The pipeline also includes 4D-710, a Phase 2 candidate for cystic fibrosis that delivers the CFTR transgene to the lungs, and 4D-175 for geographic atrophy. The company targets patients in the United States, major European markets, and Japan, focusing on chronic conditions with high unmet medical need. 4D-150 has received Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage 4dmoleculartherapeutics.com
Sector Healthcare IR page ir.4dmoleculartherapeutics.com
Tags
gene therapy, retinal diseases, cystic fibrosis, aav vectors, anti-vegf, pulmonology, genetic medicine, Therapeutic Vector Evolution, TVE, R100, 4D-150, 4D-710, 4D-175, aflibercept, CFTR
Press page —

Metrics

Valuation  
Market cap $ 723.849M
Market cap (USD) $ 723.849M
P/E -4.76
PEG —
P/BV 2.14
P/S 7.54
P/OCF -4.35
P/FCF -6.60
Dividend yield —
Turnover / mcap —
Returns  
ROE -27.6%
ROI -30.4%
ROIC -25.9%
Profit margin -164.4%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 5.8%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 49
Quality score -58.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 85.209M 37K 20.723M 3.129M 18.038M 13.363M 6.96M
Net profit -140.109M -160.868M -100.837M -107.494M -71.317M -56.693M -49.306M
Free cash flow -109.618M -138.371M -78.563M -98.221M -78.244M -51.909M -39.914M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 7.5 5.57 20.26 22.21 21.94 41.45 —
Price performance 12m 0.35 -0.73 -0.09 0.01 -0.47 — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 978,000 1.49M 47,000 0.00 — — —
↳ YoY growth +51.9% -96.8% -100.0%
Borrowings, non-current (USD) — — — — — — 0.00
Lease liabilities (USD) — 0.00 16.4M 16.1M 14.7M 24.6M 21.4M
Cash and deposits (USD) 49.7M 277M 153M 52.4M 249M 149M 60.2M
Right-of-use assets (USD) — 0.00 14.6M 13.1M 11.5M 21.1M 18.1M
Net debt (borrowings + leases - cash) (USD) — — — — — — -38.8M
Cash flow detail
Operating cash flow (USD) -36.7M -50.9M -69.1M -86.7M -75.8M -135M -109M
Purchases of property, plant and equipment (USD) -3.2M -1M -9.11M -11.5M -2.77M -3.79M -536,000
Change in receivables (cash effect) (USD) 146,000 -508,000 1.44M 47,000 0.00 — —
Change in payables (cash effect) (USD) 533,000 43,000 2.29M -1.64M 896,000 871,000 6.77M
Share-based compensation (USD) 3.54M 4.98M 13.8M 17.1M 19.7M 26.1M 22M
Operating cash flow before change in receivables (USD) -36.9M -50.4M -70.6M -86.7M -75.8M — —
Free cash flow (OCF - PPE - intangibles) (USD) -39.9M -51.9M -78.2M -98.2M -78.6M -138M -110M
Income detail
Research and development expense (USD) 38.7M 53M 61.4M 80.3M 97.1M 141M 196M
↳ 5y CAGR +29.6% +29.8%
Total comprehensive income (USD) — -56.7M -71.7M -108M -99.6M -161M -140M
Comprehensive income to owners (USD) — -56.7M -71.7M -108M -99.6M -161M -140M
Reported Mar 25, 2021 Mar 28, 2022 Mar 28, 2022 Mar 15, 2023 Feb 29, 2024 Feb 28, 2025 Aug 13, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

•Completed enrollment and randomization of the 4FRONT-2 Global Phase 3 clinical trial, the second of two pivotal trials of 4D-150 in wet AMD; topline data for 4FRONT-1 and 4FRONT-2 expected in Q2 2027 and H2 2027, respectively

•Presented 2-year data from PRISM and SPECTRA clinical trials of 4D-150 in wet AMD and DME, highlighting durable clinical activity and favorable, predictable safety profile

•Initiated 4SIGHT Global Phase 3 clinical trial of 4D-150 in DME, advancing 4D-150 into second multi-billion-dollar retinal disease market with significant unmet need

•Strengthened regulatory affairs and quality teams through the hire of Eric Floyd, PhD, MBA, as Chief Regulatory & Quality Officer

•$375 million in cash, cash equivalents and marketable securities expected to fund current operating plan into second half of 2028

EMERYVILLE, Calif., November 12, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with the potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported Q3 2026 financial results, provided

4DMT to Participate in Upcoming Investor Conferences Bull 0 Bear 0 Routine

November 3, 2026

PDF Version

EMERYVILLE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in November and December:

  • Guggenheim 3rdAnnual Healthcare Innovation Conference: Tuesday, November 10, 2026; Fireside chat at 4:30 p.m. ET

  • Stifel 2026 Healthcare Conference: Wednesday, November 11, 2026; Fireside chat at 8:00 a.m. ET

  • Jefferies Global Healthcare Conference in London: Monday, November 16, 2026; Fireside chat at 1:30 p.m. GMT

  • 9thAnnual Evercore Healthcare Conference: Tuesday, December 1, 2026; Fireside chat at 8:45 a.m. ET

  • Citi Global Healthcare Conference 2026: Wednesday, December 2, 2026; Fireside chat at 3:00 p.m. ET

  • Piper Sandler 38thAnnual Healthcare Conference: Thursday, December 3, 2026; Fireside chat at 8:30 a.m. ET

  • Barclays Virtual Ophthalmology Day: Thursday, December 10, 2026; Fireside chat at 10:30 a.m. ET

Archived copies of the webcasts will be available for up to one year on the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.

About 4DMT

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate, 4D-150, is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration and the second indication is diabetic macular edema, which are both in Phase 3 development. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, Backbone 4 Retina™ and the 4DMT logo are trademarks of 4DMT.

All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.

Learn more at www.4DMT.com and follow us on LinkedIn.

4DMT Announces New Employment Inducement Grants Bull 0 Bear 0 Routine

October 16, 2026

PDF Version

EMERYVILLE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on October 13, 2026, the compensation committee of the Company’s board of directors granted 13 new non-executive employees options to purchase an aggregate of 260,000 shares of the Company’s common stock and 157,600 Restricted Stock Units (RSUs). Each stock option has an exercise price per share equal to $12.36, which was the closing trading price on October 13, 2026, the date of grant. The stock options and RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

About 4DMT

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate, 4D-150, is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration and the second indication is diabetic macular edema, which are both in Phase 3 development. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, Backbone 4 Retina™ and the 4DMT logo are trademarks of 4DMT.

All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.

Learn more at www.4DMT.com and follow us on LinkedIn.

Prompts

4D Molecular Therapeutics, Inc. (ticker FDMT), listed in United States.

ETFs Holding 4D Molecular Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
TMED 0.32% 5,545 $ 73.749K Jun 30, 2026
FSEV 0.09% 440 $ 5,852.00 Jun 30, 2026
VFMO 0.07% 98,955 $ 1.396M Aug 31, 2026
AVSC 0.04% 117,465 $ 1.326M Nov 16, 2026
RESM 0.02% 55 $ 731.50 Jun 30, 2026
FESM 0.01% 50,196 $ 667.607K Jun 30, 2026
DFAS 0.01% 301,332 $ 3.651M Nov 12, 2026
DXUV 0.00% 21,020 $ 254.657K Nov 12, 2026
DFAC 0.00% 128,235 $ 1.554M Nov 12, 2026
DFSU 0.00% 3,210 $ 38.889K Nov 12, 2026
DCOR 0.00% 51,476 $ 623.632K Nov 12, 2026
DFAU 0.00% 11,287 $ 136.742K Nov 12, 2026
DFUS 0.00% 13,010 $ 157.616K Nov 12, 2026
AVUS 0.00% 7,394 $ 83.478K Nov 16, 2026